{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:28Z","timestamp":1786119628400,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/aog.0b013e318187e1c5","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T07:28:28Z","timestamp":1291102108000},"page":"773-781","source":"Crossref","is-referenced-by-count":52,"title":["Treatment of Acne Using a 3-Milligram Drospirenone\/20-Microgram Ethinyl Estradiol Oral Contraceptive Administered in a 24\/4 Regimen"],"prefix":"10.1097","volume":"112","author":[{"given":"J Michael","family":"Maloney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoo","family":"Niknian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooji","family":"Lee-Rugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Sampson-Landers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Korner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210126","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2165\/00003495-200363150-00005","article-title":"Current concepts of the pathogenesis of acne: implications for drug treatment.","volume":"63","author":"Gollnick","year":"2003","journal-title":"Drugs"},{"key":"R2-8-20210126","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0029-7844(97)00059-8","article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.","volume":"89","author":"Redmond","year":"1997","journal-title":"Obstet Gynecol"},{"key":"R3-8-20210126","first-page":"2","article-title":"The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.","volume":"69","author":"van Vloten","year":"2002","journal-title":"Cutis"},{"key":"R4-8-20210126","first-page":"123","article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.","volume":"74","author":"Thorneycroft","year":"2004","journal-title":"Cutis"},{"key":"R5-8-20210126","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.contraception.2004.12.005","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 20 \u03bcg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.","volume":"71","author":"Klipping","year":"2005","journal-title":"Contraception"},{"key":"R6-8-20210126","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"R7-8-20210126","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13625180008500387","article-title":"A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel [published erratum appears in Eur J Contracept Reprod Health Care 2001;6:63].","volume":"5","author":"Foidart","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R8-8-20210126","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-73-4-837","article-title":"Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women.","volume":"73","author":"Oelkers","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-8-20210126","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","article-title":"Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.","volume":"106","author":"Yonkers","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R10-8-20210126","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 \u03bcg ethinylestradiol and 3 mg drospirenone.","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"R11-8-20210126","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2005.08.021","article-title":"Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.","volume":"72","author":"Pearlstein","year":"2005","journal-title":"Contraception"},{"key":"R12-8-20210126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2007.11.003","article-title":"Efficacy and safety of 3 mg drospirenone\/20 mcg ethinylestradiol oral contraceptive administered in 24\/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.","volume":"77","author":"Koltun","year":"2008","journal-title":"Contraception"},{"key":"R13-8-20210126","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1067\/mjd.2002.122192","article-title":"Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial.","volume":"47","author":"Leyden","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R14-8-20210126","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0190-9622(97)70112-9","article-title":"Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.","volume":"37","author":"Lucky","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"R15-8-20210126","first-page":"461","article-title":"A randomized, controlled trial of a low-dose contraceptive containing 20 \u03bcg of ethinyl estradiol and 100 \u03bcg of levonorgestrel for acne treatment.","volume":"76","author":"Thiboutot","year":"2001","journal-title":""}],"container-title":["Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-200810000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:36Z","timestamp":1786041936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-200810000-00008"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0b013e318187e1c5","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}